Timothy Cooper1, Vincent L Biron1, Ben Adam2, Alexander C Klimowicz3, Lakshmi Puttagunta2, Hadi Seikaly1. 1. Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Alberta Hospital, Edmonton, Alberta, Canada. 2. Department of Laboratory Medicine and Pathology, University of Alberta Hospital, Edmonton, Alberta, Canada. 3. Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Abstract
IMPORTANCE: Keratinization is a histologic feature on hematoxylin-eosin staining associated with adverse outcomes in head and neck cancer, particularly oral cavity squamous cell carcinoma. However, the prognostic value of keratinization has not been demonstrated in oropharyngeal squamous cell carcinoma (OPSCC) in a large cohort of patients. OBJECTIVE: To quantify the prognostic value of keratinization in a large cohort of patients with OPSCC with subgroup analysis based on p16 status, basaloid differentiation, and smoking status. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cross-sectional study using a prospectively collected database that identified 208 patients with OPSCC diagnosed and treated at a single tertiary cancer center from 2002 to 2009. Tissue microarrays (TMAs) were generated from 208 patient specimens stained with hematoxylin-eosin and immunohistochemical markers. Digital images from stained TMAs were scored for the presence of keratinization and/or basaloid differentiation and for p16 status. INTERVENTIONS: Patients were treated with curative intent with surgery, radiation, and/or chemotherapy. MAIN OUTCOMES AND MEASURES: The primary outcome measure was 5-year disease-specific survival (DSS) in OPSCC according to keratinization. Univariate and multivariate survival analyses were performed to estimate survival according to histopathologic profile and smoking status. RESULTS: In the 208 samples, 96 were keratinizing and 112 were nonkeratinizing. Patients with keratinizing tumors were more likely to have advanced-stage disease and be p16 negative. Keratinization was independently associated with adverse outcomes. The 5-year DSS was significantly higher for nonkeratinizing tumors (63.3%) compared with keratinizing tumors (44.8%; P = .007). In subgroup analysis, nonkeratinization was associated with improved DSS in those with nonbasaloid and p16-negative tumors and in patients who were smokers. When stratifying patients based on keratinization, p16-status, and smoking status, patients with p16-negative keratinizing tumors who were smokers had the lowest 5-year DSS (26.7%). CONCLUSIONS AND RELEVANCE: Patients with nonkeratinized OPSCC have improved survival compared with those with keratinizing tumors. Information on keratinization is most useful prognostically in those who have p16-negative and nonbasaloid tumors and in patients who are smokers. Survival can be stratified using keratinization, p16 status, and smoking status.
IMPORTANCE: Keratinization is a histologic feature on hematoxylin-eosin staining associated with adverse outcomes in head and neck cancer, particularly oral cavity squamous cell carcinoma. However, the prognostic value of keratinization has not been demonstrated in oropharyngeal squamous cell carcinoma (OPSCC) in a large cohort of patients. OBJECTIVE: To quantify the prognostic value of keratinization in a large cohort of patients with OPSCC with subgroup analysis based on p16 status, basaloid differentiation, and smoking status. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cross-sectional study using a prospectively collected database that identified 208 patients with OPSCC diagnosed and treated at a single tertiary cancer center from 2002 to 2009. Tissue microarrays (TMAs) were generated from 208 patient specimens stained with hematoxylin-eosin and immunohistochemical markers. Digital images from stained TMAs were scored for the presence of keratinization and/or basaloid differentiation and for p16 status. INTERVENTIONS:Patients were treated with curative intent with surgery, radiation, and/or chemotherapy. MAIN OUTCOMES AND MEASURES: The primary outcome measure was 5-year disease-specific survival (DSS) in OPSCC according to keratinization. Univariate and multivariate survival analyses were performed to estimate survival according to histopathologic profile and smoking status. RESULTS: In the 208 samples, 96 were keratinizing and 112 were nonkeratinizing. Patients with keratinizing tumors were more likely to have advanced-stage disease and be p16 negative. Keratinization was independently associated with adverse outcomes. The 5-year DSS was significantly higher for nonkeratinizing tumors (63.3%) compared with keratinizing tumors (44.8%; P = .007). In subgroup analysis, nonkeratinization was associated with improved DSS in those with nonbasaloid and p16-negative tumors and in patients who were smokers. When stratifying patients based on keratinization, p16-status, and smoking status, patients with p16-negative keratinizing tumors who were smokers had the lowest 5-year DSS (26.7%). CONCLUSIONS AND RELEVANCE: Patients with nonkeratinized OPSCC have improved survival compared with those with keratinizing tumors. Information on keratinization is most useful prognostically in those who have p16-negative and nonbasaloid tumors and in patients who are smokers. Survival can be stratified using keratinization, p16 status, and smoking status.
Authors: Justin R Shinn; Seth J Davis; Krystle A Lang-Kuhs; Sarah Rohde; Xiaowei Wang; Ping Liu; William D Dupont; Dale Plummer; Wade L Thorstad; Rebecca D Chernock; Mitra Mehrad; James S Lewis Journal: Am J Surg Pathol Date: 2021-07-01 Impact factor: 6.298
Authors: Hani Z Marzouki; Vincent L Biron; Peter T Dziegielewski; Andrew Ma; Jason Vaz; Gabriela Constantinescu; Jeffrey Harris; Daniel O'Connell; Hadi Seikaly Journal: J Otolaryngol Head Neck Surg Date: 2018-09-19
Authors: Siyu Liu; Marcell Costa de Medeiros; Evan M Fernandez; Katie R Zarins; Raymond G Cavalcante; Tingting Qin; Gregory T Wolf; Maria E Figueroa; Nisha J D'Silva; Laura S Rozek; Maureen A Sartor Journal: Clin Epigenetics Date: 2020-11-17 Impact factor: 6.551
Authors: Sanne A M van Lith; Fokko J Huizing; Gerben M Franssen; Bianca A W Hoeben; Jasper Lok; Sofia Doulkeridou; Otto C Boerman; Martin Gotthardt; Paul M P van Bergen En Henegouwen; Johan Bussink; Sandra Heskamp Journal: Mol Pharm Date: 2022-01-19 Impact factor: 5.364